GRFS
HealthcareGrifols, S.A.
$9.32
+$0.08 (+0.87%)
Jan 5, 2026
Price History (1Y)
Analysis
Grifols, S.A. operates in the healthcare sector, specifically within the drug manufacturers - general industry. The company has a significant scale, with a market capitalization of $7.69B and annual revenues of $7.52B. It employs approximately 23,800 people. Financially, Grifols demonstrates solid profitability metrics, including a gross margin of 39.8%, operating margin of 20.4%, and profit margin of 5.0%. The company's return on equity is 5.9% and its return on assets is 4.6%. However, it has a substantial debt-to-equity ratio of 128.35, indicating a relatively high level of indebtedness. Grifols maintains sufficient liquidity with cash reserves of $825.48M and a current ratio of 2.48. Grifols' valuation metrics reveal an earnings multiple of 14.34 (TTM) and a forward P/E of 7.80. The company's revenue growth rate is 4.0% on a year-over-year basis, while its dividend yield stands at 190.0%, with a payout ratio of 27.5%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Grifols, S.A.
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Visit website →Key Statistics
- Market Cap
- $7.69B
- P/E Ratio
- 14.34
- 52-Week High
- $11.14
- 52-Week Low
- $6.19
- Avg Volume
- 595.72K
- Beta
- 1.21
- Dividend Yield
- 190.00%
Company Info
- Industry
- Drug Manufacturers - General
- Exchange
- NMS
- Country
- Spain
- Employees
- 23,800